glp 1 agonist nash Frontiers Upcoming GLP-1 RAs for NASH:

The recommended dose is 5 mcg twice daily initially, which may be increased to 10 mcg twice daily after one month based on clinical response and tolerability

It is also worth noting that these effects of liraglutide in OVX animals occurred relatively quickly, with positive outcomes observed after just four weeks of treatment, consistent with in vitro data [57]

UK Prospective Diabetes Study (UKPDS) Group

He L, et al

A comprehensive analysis of 43,365 individuals from two US healthcare databases indicated that GLP-1 RAs do not elevate the risk of pulmonary aspiration during upper gastrointestinal endoscopy in patients with T2DM when compared to SGLT-2 inhibitors, yielding a pooled risk ratio of 0.98 (95% CI, 0.73 to 1.31) among GLP-1 RA users

Beyond quantitative preservation, maintaining skeletal muscle function, including strength and metabolic capacity, remains a critical therapeutic goal in ensuring long-term health outcomes